Long-term surviving patient with EGFR mutation - deletion on exon 79 and acquired resistant mutation T790 - case report
Abstract
Metastatic lung cancer has a very poor prognosis, with a 5-year survival of about 5%. Pulmonary malignan-cies with a control mutation for which biologically targeted drugs are available have a better prognosis, as shown by a case report of a patient with a sensitive control EGFR mutation.
Tumor biopsy and peripheral blood sampling, liquid biopsy, were performed repeatedly duringtreatmentto detect the acquired T790 resistance mutation, among other things. The patient survives with metastatic lung adenocarcinoma for eight years, still with a good quality of life.
The case report shows that due to a suitably selected treatment sequence according to the presumed or known genetic profile of the tumor, even metastatic lung cancer can change from such a serious disease to a chronic one.